Insuman Infusat (Insulin Human)

Insulin Human is a recombinant form of the hormone insulin that binds to insulin receptors on muscle, fat, and liver cells. This binding activates intracellular signaling that promotes glucose transporter‑4 translocation, increases glucose uptake, and suppresses hepatic glucose production, thereby lowering circulating glucose concentrations.

The dose of Insuman Infusat is individualized and determined by the prescribing healthcare professional based on the patient’s age, weight, type of diabetes, current glycemic control, and concurrent therapies. The prescriber calculates the appropriate units per injection and may adjust the regimen over time according to blood glucose monitoring.

Safety of Insuman Infusat during pregnancy or lactation has not been definitively established. Insulin is generally considered the preferred glucose‑lowering therapy for pregnant women with diabetes, but the decision to use this product should be made by the treating physician after weighing potential benefits against any unknown risks.

To request Insuman Infusat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain logistics if needed—and assistance with import documentation.

Insuman Infusat contains recombinant human insulin, which has a pharmacokinetic profile similar to endogenous insulin and differs from rapid‑acting analogues that have modified amino‑acid sequences for faster onset. Compared with insulin analogues, human insulin may have a slightly longer onset and duration, making it suitable for basal coverage but potentially requiring more frequent dosing adjustments.

Insuman Infusat should be stored in a refrigerator at 2 °C to 8 °C, protected from light and moisture. Do not freeze the product; if it becomes frozen, discard it. Once in use, the vial may be kept at room temperature (up to 30 °C) for a maximum of 28 days, and the needle‑syringe should be used promptly to maintain sterility.

Insuman Infusat is administered by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection site should be rotated to reduce the risk of lipodystrophy. The prescriber determines the injection volume and frequency, which may range from once daily to multiple daily doses depending on the patient’s insulin requirements.

The most serious risks associated with Insuman Infusat include severe hypoglycemia, which can cause loss of consciousness, seizures, or coma, and allergic reactions such as anaphylaxis, urticaria, or angioedema. Patients should be educated to recognize early signs of low blood sugar and to seek immediate medical attention if an allergic response occurs.

Insuman Infusat is contraindicated in individuals with a known hypersensitivity to human insulin or any of its excipients. It should also be avoided in patients experiencing hypoglycemia until glucose levels are corrected, and in those with severe renal or hepatic failure where dose adjustment may be insufficient to prevent adverse effects.